Immunotherapy for Merkel Cell Carcinoma

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2021 Feb 17

PMID 33595894

Citations 13

Authors

Christina V Angeles

Michael S Sabel

Affiliations

Soon will be listed here.

Abstract

Merkel cell carcinoma (MCC) is an aggressive form of skin cancer which, while chemosensitive, has high rates of relapse and chemoresistance, limiting the impact of chemotherapy. An immunogenic tumor, the management of advanced MCC has changed dramatically with the introduction of checkpoint inhibitors. This review will focus on the impact of immunotherapy in unresectable and metastatic MCC, ongoing research in the adjuvant and neoadjuvant settings, and future directions of immune-based strategies for this challenging cancer.

Citing Articles

Low Intratumoral CD200 Protein Expression in Primary Merkel Cell Carcinoma Is a Strong Predictor for Disease Relapse.

Gambichler T, Girke S, Abu Rached N, Susok L, Becker J, Schulze H Cancers (Basel). 2025; 17(5).

PMID: 40075669 PMC: 11899218. DOI: 10.3390/cancers17050822.

An Unusual Complete Response to Immunotherapy in a Locoregional Recurrent Merkel Cell Carcinoma.

Correa Roa C, Laxague F, Fernandez Vila J Cureus. 2025; 17(1):e77152.

PMID: 39925521 PMC: 11805602. DOI: 10.7759/cureus.77152.

Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models.

Pedersen E, Verhaegen M, Joseph M, Harms K, Harms P Front Oncol. 2024; 14:1413793.

PMID: 39136002 PMC: 11317257. DOI: 10.3389/fonc.2024.1413793.

Knockdown of nicotinamide N-methyltransferase suppresses proliferation, migration, and chemoresistance of Merkel cell carcinoma cells in vitro.

Pozzi V, Molinelli E, Campagna R, Serritelli E, Cecati M, De Simoni E Hum Cell. 2024; 37(3):729-738.

PMID: 38504052 PMC: 11016511. DOI: 10.1007/s13577-024-01047-0.

An Investigation of Structure-Activity Relationships and Cell Death Mechanisms of the Marine Alkaloids Discorhabdins in Merkel Cell Carcinoma Cells.

Orfanoudaki M, Smith E, Hill N, Garman K, Brownell I, Copp B Mar Drugs. 2023; 21(9).

PMID: 37755087 PMC: 10532587. DOI: 10.3390/md21090474.